The Tomosynthesis Mammographic Imaging Screening Trial, known as TMIST or study EA1151, is a breast cancer screening trial of nearly 165,000 healthy women that is set to begin recruiting participants in the United States and Canada in the early fall of 2017. TMIST is the first randomized trial in the world to compare two standard types of digital mammograms for breast cancer screening: tomosynthesis (also called 3-D) and conventional (also called 2-D). While 3-D mammography is the newer technology, it is not widely available and researchers do not know whether it is better than conventional mammography at detecting aggressive, life-threatening types of breast cancer early, before they become advanced and more difficult to treat. This study aims to help women and their doctors in the future decide the best ways to screen for breast cancer, considering their own individual risk factors for developing the disease.
TMIST is funded by the National Cancer Institute’s Division of Cancer Prevention, part of the National Institutes of Health.
Physician and Research Staff Educational Materials:
These materials are intended for promotional use among health care professionals and are NOT intended for use as patient educational materials.
Participating mammography clinics (sites) should note that the Central Institutional Review Board (CIRB) has approved this material. For sites utilizing local IRBs, please submit this in accordance with your local IRB policies prior to use.
Additional Information on ClinicalTrials.gov: Displayed below is an interactive view of the study record as it appears in the government registry. If you are experiencing technical difficulties with this view, visit clinicaltrials.gov and search for record NCT03233191 .